Next Quarterly Earnings
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
UroGen Pharma is a US-based biotechnology company specializing in the development of innovative therapies for urological cancers. Through its proprietary RTGel technology, UroGen enables new, minimally invasive treatment approaches for patients suffering from urothelial carcinomas.
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
UroGen Pharma is scheduled to report its next quarterly earnings on 11/05/2026. Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
UroGen Pharma last reported quarterly earnings on 8/5/2026 (Q2 2026). Earnings per share (EPS) came in at -0.28 USD.
Across its last 3 earnings reports, UroGen Pharma stock moved by ±12.9% on average the following day. The largest reaction was +16.3% on 08/05/2026; 2 of 3 reactions were positive.
UroGen Pharma has beaten analyst EPS estimates in 1 of its last 5 evaluated quarters (beat rate: 20%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 3 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.